secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001193125-23-289530
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director John F. Crowley resigns from Intellia Therapeutics Board
-----------------------------------------------------------------

- John F. Crowley resigned from the Board and its committees effective December 5, 2023.
- He served on Nominating and Governance and Compensation and Talent Development Committees.
- Resignation is not due to any disagreement with the Company on operations, policies, or practices.
- No replacement has been announced as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523289530/0001193125-23-289530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523289530/d12624d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-289530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer